Thrombosis News and Research

Latest Thrombosis News and Research

STENTYS initiates enrollment in Self-Apposing Sirolimus-eluting stent trial for heart attack

STENTYS S.A., a medical technology company commercializing the world's first and only Self-Apposing Stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the first patient in its 'APPOSITION IV' clinical study using its new Self-Apposing Sirolimus-eluting stent.

From Medtronic 15 Jun 2012

Uncertainty over efficacy of clopidogrel in hemolytic uremic syndrome

Clinical outcomes for children hospitalized with diarrhea-associated hemolytic uremic syndrome are comparable between those treated with clopidogrel and those who are not, show study findings.

12 Jun 2012

CRT, BioInvent partner to identify new therapeutic antibodies in oncology

BioInvent International AB and Cancer Research Technology Ltd (CRT), the commercial arm of Cancer Research UK, announced today that they have entered a collaboration with Queen Mary, University of London, to identify new therapeutic antibodies in oncology.

12 Jun 2012

Mechanochemical ablation catheter as effective as current endothermal techniques

In its first human trial, the mechanochemical ablation (MOCA) catheter was efficacious at two years as current endothermal techniques, but without the need of tumescent anesthesia. In addition, MOCA was more effective than results of foam sclerotherapy of the great saphenous vein (GSV) and is another alternative modality for most incompetent GSV's and small saphenous veins.

10 Jun 2012

Branches following complex aortic aneurysm repair appear to be durable: Study

Branches following complex aortic aneurysm repair appear to be durable and are rarely the cause of patient death following complex aortic aneurysm repair according to a study presented at the 66th Vascular Annual Meeting presented by the Society for Vascular Surgery.

8 Jun 2012

Aspirin linked to high bleeding rate in diabetes

Diabetes may be associated with an increased risk for major bleeding irrespective of aspirin use, researchers say.

7 Jun 2012

Aeterna Zentaris announces results from perifosine Phase 1 trial on multiple myeloma

Aeterna Zentaris Inc. today announced that Phase 1 trial results for the Company's oral anticancer compound, perifosine, in multiple myeloma, have been published in the online May 2012 issue of the British Journal of Haematology.

6 Jun 2012

BioInvent, ThromboGenics to regain global rights to TB-403 from Roche

ThromboGenics NV and co-development partner BioInvent International announce today that they will regain global rights to TB-403 from Roche.

6 Jun 2012

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

Exelixis, Inc. today reported positive updated interim data from an ongoing phase 2 trial of cabozantinib in men with metastatic castration-resistant prostate cancer (CRPC) and bone metastases.

6 Jun 2012

BioInvent, ThromboGenics announce results from TB-402 Phase IIb trial on VTE

ThromboGenics NV and co-development partner BioInvent International announce today the results from a Phase IIb trial comparing TB-402, a long acting anticoagulant, against rivaroxaban, an oral anticoagulant.

5 Jun 2012

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

5 Jun 2012

Exelixis reports data from cabozantinib phase 3 trial on MTC

Exelixis, Inc. today reported data from the phase 3 pivotal trial of cabozantinib in patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).

5 Jun 2012

Thrombosis biomarker levels differ according to thrombolysis strategy

An early invasive strategy following thrombolysis for ST-segment-elevation myocardial infarction is associated with significant changes in the levels of inflammatory and thrombotic biomarkers, a substudy of the Norwegian study on district treatment of STEMI shows.

31 May 2012

UCSB creates synthetic platelets for various biomedical applications

Synthetic platelets have been developed by UC Santa Barbara researchers, in collaboration with researchers at Scripps Research Institute and Sanford-Burnham Institute in La Jolla, Calif. Their findings are published in the journal Advanced Materials in a paper titled "Platelet Mimetic Particles for Targeting Thrombi in Flowing Blood."

31 May 2012

FDA clears Teleflex’s ARROW PICC with Chloragard technology

Teleflex Incorporated announced today that in addition to broad-spectrum antimicrobial protection, the pressure-injectable ARROW PICC with Chloragard Technology provides antithrombogenic protection for at least 30 days.

22 May 2012

$Children with pelvic and thigh fractures rarely develop dangerous blood clots$

Children with pelvic and thigh fractures rarely develop dangerous blood clots

Children with pelvic and thigh fractures develop dangerous blood clots so rarely that anti-clotting therapy should be given only to those with underlying conditions that increase clotting risk, according to a study from Johns Hopkins Children's Center.

21 May 2012

$Anti-clotting drugs rarely needed in children with big-bone fractures$

Anti-clotting drugs rarely needed in children with big-bone fractures

21 May 2012

Boston Scientific announces two-year results from PLATINUM Small Vessel study

Boston Scientific Corporation announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element Everolimus-Eluting Platinum Chromium (PtCr) Stent System in treating de novo coronary lesions in small coronary vessels.

19 May 2012

Quasi-experimental data supports argument that air pollution may be a global risk factor for CVD

During the 2008 Beijing Olympics, changes in air pollution were associated with changes in biomarkers of systemic inflammation and thrombosis (formation of blood clot) as well as measures of cardiovascular physiology in healthy young persons, according to a study in the May 16 issue of JAMA, a theme issue on Global Health.

16 May 2012

Research roundup: Health providers' growing clout; The surprising bargain in Part D costs

The Growing Power Of Some Providers To Win Steep Payment Increases From Insurers Suggests Policy Remedies May Be Needed -- Concerns have grown that the consolidation of hospitals and physician groups has increased their ability to raise prices, which increases costs for insurers and patients.

11 May 2012